Ovid Therapeutics Inc. (OVID) intrinsic value & 10-year financials
Ovid Therapeutics Inc. (OVID) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 10.5% a year to $7.3M, with an average return on invested capital of -233.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.15
- Market cap
- $151.7M
- Revenue (FY2025)
- $7.3M
- Revenue growth (10-yr CAGR)
- -10.5%
- ROIC (10-yr avg)
- -233.6%
- Free cash flow (FY2025)
- -$38.3M
OVID 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $7.3M | -$17.4M | — | -$38.3M | -585.2% | -45.9% |
| FY2024 | $566.0K | -$26.4M | — | -$56.0M | -10933.7% | -94.6% |
| FY2023 | $222.8M | -$52.3M | -$0.74 | -$45.8M | -26.6% | -66.3% |
| FY2022 | $222.5M | -$54.2M | -$0.77 | -$56.5M | -25.0% | -116.5% |
| FY2021 | $221.0M | $122.8M | $1.76 | $118.4M | 56.2% | -1526.2% |
| FY2020 | $12.6M | -$81.0M | -$1.39 | -$51.7M | -645.4% | -143.3% |
| FY2019 | — | -$60.5M | — | -$51.1M | — | -112.9% |
| FY2018 | — | -$52.0M | — | -$45.6M | — | -86.6% |
| FY2017 | — | -$64.8M | — | -$31.5M | — | -98.0% |
| FY2016 | — | -$22.4M | — | -$17.8M | — | -45.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Ovid Therapeutics Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Ovid Therapeutics Inc. has historically struggled to out-earn its cost of capital, averaging just -82.5% ROIC.
Ovid Therapeutics Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Ovid Therapeutics Inc. is modeled at -10.5% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-18.92 per share.